Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 271 publications

Targeted Therapies Modulating Mesenchymal-Epithelial Transition-Linked Oncogenic Signaling in the Tumor Microenvironment: Comparative Profiling of Capmatinib, Bemcentinib, and Galunisertib.

Targeted Therapies Modulating Mesenchymal-Epithelial Transition-Linked Oncogenic Signaling in the Tumor Microenvironment: Comparative Profiling of Capmatinib, Bemcentinib, and Galunisertib.

Journal: Journal of clinical medicine
Published: August 29, 2025

MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies.

MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies.

Journal: Targeted oncology
Published: June 25, 2025

Low-energy room-temperature carbon dots for targeted sensing of MET inhibitor capmatinib.

Low-energy room-temperature carbon dots for targeted sensing of MET inhibitor capmatinib.

Journal: RSC advances
Published: June 18, 2025

The pharmacokinetics of capmatinib and its efficacy in non-small cell lung cancer treatment: a narrative review.

The pharmacokinetics of capmatinib and its efficacy in non-small cell lung cancer treatment: a narrative review.

Journal: Translational lung cancer research
Published: June 17, 2025

Evolving roles of MET as a therapeutic target in NSCLC and beyond.

Evolving roles of MET as a therapeutic target in NSCLC and beyond.

Journal: Nature reviews. Clinical oncology
Published: June 12, 2025

Molecular Profiling: Genomic-Guided Therapy for Lung Adenocarcinoma.

Molecular Profiling: Genomic-Guided Therapy for Lung Adenocarcinoma.

Journal: Cureus
Published: May 25, 2025

Remarkable Efficacy of Capmatinib in a Patient with Cancer of Unknown Primary with MET Amplification: A Case Report.

Remarkable Efficacy of Capmatinib in a Patient with Cancer of Unknown Primary with MET Amplification: A Case Report.

Journal: Internal medicine (Tokyo, Japan)
Published: May 21, 2025

PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma.

PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma.

Journal: Cellular oncology (Dordrecht, Netherlands)
Published: May 15, 2025

Fe-MOF loaded with capmatinib to reverse immunosuppressive microenvironment and inhibit tumor metastasis after radiofrequency ablation.

Fe-MOF loaded with capmatinib to reverse immunosuppressive microenvironment and inhibit tumor metastasis after radiofrequency ablation.

Journal: Journal of nanobiotechnology
Published: May 13, 2025

HGF/c-MET axis contributes to CLL cell survival by regulating multiple mechanisms making it a potential therapeutic target for CLL treatment.

HGF/c-MET axis contributes to CLL cell survival by regulating multiple mechanisms making it a potential therapeutic target for CLL treatment.

Journal: Frontiers in pharmacology
Published: April 16, 2025

Adverse event signal analysis of type Ib MET tyrosine kinase inhibitors based on food and drug administration adverse event reporting system.

Adverse event signal analysis of type Ib MET tyrosine kinase inhibitors based on food and drug administration adverse event reporting system.

Journal: Expert opinion on drug safety
Published: April 03, 2025

CRE25-033: A MET Amplified Metastatic Esophageal Adenocarcinoma Demonstrates Response to the MET Inhibitor Capmatinib.

CRE25-033: A MET Amplified Metastatic Esophageal Adenocarcinoma Demonstrates Response to the MET Inhibitor Capmatinib.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 29, 2025
Showing 1-12 of 271

Last Updated: 10/31/2025